peri-menopause and post-menopause
Conditions
Interventions
standard dose group:1mg estradiol
low dose group:0.5mg estradiol
extra dose group:0.25mg estradiol
control:none
Sponsors
Women's Hospital School Of Medicine Zhejiang University
Eligibility
Sex/Gender
Female
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Signed informed consent, who volunteered to participate in this study; 2. Aged 40-60 years peri-menopausal women and postmenopausal women, be amenorrhea within 10 years, have some menopausal symptom, such as vasomotor symptoms (hot flashes, night sweats) and vaginal dryness and discomfort ect.; 3. requesting for treatment without menopausal symtoms.
Exclusion criteria
Exclusion criteria: 1. women with contraindications of HRT, including Unexplained vaginal bleeding, or known or suspected estrogen-dependent tumor, or thromboembolic disease or thrombophilia in the past 6 months; or severe liver and kidney dysfunction etc.; 2. women receiving or received glucocorticoids, estrogens, statins, thyroid hormone, fluoride, bisphosphonate, calcitonin, thiazide diuretics, barbiturates, antiseizure medications, vitamin D, or calcium-containing drugs in the past 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| follicle-stimulating hormone;estradiol;Body Mass Index;waistline;Kupperman Index;low density lipoprotein;cholesterol;blood glucose;insulin;collagen type I crosslinked C-telopeptide;procollagen type I N-terminal propeptide; | — |
Countries
China
Contacts
Public ContactJianhong Zhou
Women's Hospital School Of Medicine Zhejiang University
Outcome results
None listed